ImmunityBio, Inc. (NASDAQ:IBRX) is a top healthcare stock, reporting 60% revenue growth in Q2 2025, totaling $26.4 million. Key milestone: FDA approval for ANKTIVA immunotherapy for bladder cancer, with expanding clinical use. Recent UK regulatory approval for ANKTIVA plus BCG. Company raised $80 million for further development and expansion.

Transitioning from clinical to commercial stage, ImmunityBio, Inc. (NASDAQ:IBRX) sees ANKTIVA adoption accelerating. Drug reduces need for invasive treatments like cystectomy for bladder cancer, showing durable bladder preservation in responders. While IBRX shows investment potential, some AI stocks may offer greater upside. Explore opportunities in AI stocks for potential growth.

Looking for investment opportunities beyond healthcare stocks like ImmunityBio, Inc. (NASDAQ:IBRX)? Consider exploring undervalued AI stocks with significant upside potential. Find out more about a promising short-term AI stock that could benefit from current economic trends. For more insights on potential investments, check out our report on the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks with high growth potential.

Read more at Yahoo Finance: ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates